CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA
CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA
复制标题
DOI：
10.1097/iae.0b013e31818358b2
复制
发表时间：
2008-10-01
影响因子：
3.3
通讯作者：
Pang, Chi-Pui
中科院分区：
文献类型：
--
作者：
Chan, Wai-Man;Lai, Timothy Y. Y.;Pang, Chi-Pui
背景资料：评估玻璃体内注射贝伐单抗治疗继发于年龄相关性黄斑变性或病理性近视的脉络膜新生血管（CNV）后，房水血管内皮生长因子（VEGF）和色素上皮衍生因子（PEDF）的变化。在注射时从51名患者的51只眼睛获得房水样品，这些患者在基线、1，两个月。使用酶联免疫吸附测定法评估并比较房水中VEGF和PEDF的浓度。对于34只患有年龄相关性黄斑变性CNV的眼睛，平均+/-标准差的水性VEGF水平从基线时的102.6 μ g/mL +/- 90.6 pg/mL降至2个月时的18.3 pg/mL +/- 22.5 pg/mL（P < 0.001），而平均PEDF水平从基线时的11.2 ng/mL +/- 10.4 ng/mL增加到2个月时的38.7 ng/mL +/- 47.9 ng/mL（P = 0.001）。对于17只患有近视CNV的眼睛，平均标准差水性VEGF水平从基线时的20.1 pg/mL +/- 28.9 pg/mL降至2个月时的3.8 pg/mL +/- 5.3 pg/mL（P = 0.016），而平均PEDF水平从基线时的20.0 ng/mL +/- 16.3 ng/mL增加到2个月时的126.0 ng/mL +/- 152.0 ng/mL结论：玻璃体内注射贝伐单抗可降低继发于年龄相关性黄斑变性或病理性近视的CNV患者的房水VEGF水平，增加PEDF水平。这些变化可能有利于抑制CNV血管生成。视网膜28：1308-1313，2008
Background: To evaluate the changes in aqueous vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) following intravitreal bevacizumab injections for choroidal neovascularization (CNV) secondary to age-related macular degeneration or pathologic myopia.Methods: Aqueous samples were obtained at the time of injection from 51 eyes of 51 patients who underwent three monthly intravitreal bevacizumab (Avastin) injections at baseline, 1, and 2 months. Concentrations of VEGF and PEDF in the aqueous were evaluated using enzyme-linked immunosorbent assay and compared.Results: For the 34 eyes with age-related macular degeneration CNV, the mean +/- standard deviation aqueous VEGF level reduced from 102.6 mu g/mL +/- 90.6 pg/mL at baseline to 18.3 pg/mL +/- 22.5 pg/mL at 2 months (P < 0.001), whereas the mean PEDF level increased from 11.2 ng/mL +/- 10.4 ng/mL at baseline to 38.7 ng/mL +/- 47.9 ng/mL at 2 months (P = 0.001). For the 17 eyes with myopic CNV, the mean standard deviation aqueous VEGF level reduced from 20.1 pg/mL +/- 28.9 pg/mL at baseline to 3.8 pg/mL +/- 5.3 pg/mL at 2 months (P = 0.016), whereas the mean PEDF level increased from 20.0 ng/mL +/- 16.3 ng/mL at baseline to 126.0 ng/mL +/- 152.0 ng/mL at 2 months (P = 0.016).Conclusions: Intravitreal bevacizumab injections resulted in reduced aqueous VEGF and increased PEDF levels in patients with CNV secondary to age-related macular degeneration or pathologic myopia. These changes may be favorable for the inhibition of CNV angiogenesis. RETINA 28:1308-1313, 2008